High Nuclear S100A6 (Calcyclin) Is Significantly Associated with Poor Survival in Pancreatic Cancer Patients
Dale Vimalachandran(University Hospital of Wales), Eithne Costello(University of Liverpool), Nicholas R. Lemoine(Queen Mary University of London), Tatjana Crnogorac‐Jurcevic(Queen Mary University of London), William Greenhalf(University of Liverpool), Jütta Lüttges(Christian-Albrechts-Universität zu Kiel), Christopher C. Thompson(Brigham and Women's Hospital), John P. Neoptolemos(University of Liverpool), Wendy Prime(University of Liverpool), Richard L. Watson(Northwestern University), Fiona Campbell(University of Birmingham), Andrew Dodson(National Health Service)
Cited by 143
Related Papers
What is meant by intention to treat analysis? Survey of published randomised controlled trials
|BMJ|1999|2.2k
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Effectiveness of brief alcohol interventions in primary care populations
|Cochrane Database of Systematic Reviews|2018|1.7k